


Dentsply Sirona

November 5, 2026

Third Quarter 2026 Earnings Conference Call

Forward-Looking Statements and Associated Risks

All statements in this Presentation that do not directly and exclusively relate to historical facts constitute "forward-looking statements." Such statements are subject to numerous assumptions, risks, uncertainties and other factors that could cause actual results to differ materially from those described in such statements. Many of these factors are outside of our control, including those described in Part I, Item 1A, "Risk Factors" of the Company's most recent Annual Report on Form 10-K, Part II, Item 1A, "Risk Factors" of the Company's Quarterly Reports on Form 10-Q for any subsequent fiscal quarters, and any updating information or other factors which may be described in the Company's other filings with the Securities and Exchange Commission (the "SEC"). No assurance can be given that any result, expectation, belief, goal or plan set forth in any forward-looking statement can or will be achieved, and readers are cautioned not to place undue reliance on such statements which speak only as of the date they are made. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this Presentation or to reflect the occurrence of unanticipated events. Investors should understand it is not possible to predict or identify all relevant risks and other factors which could cause actual results to differ materially from statements made on the basis of our current expectations and beliefs. As such, you should not consider the risks identified in the Company's SEC filings to be a complete discussion of all potential risks or uncertainties associated with an investment in the Company.

Non-GAAP Financial Measures

In addition to results determined in accordance with U.S. generally accepted accounting principles ("U.S. GAAP"), the Company provides certain measures in this Presentation, which are not calculated in accordance with U.S. GAAP and therefore represent Non-GAAP measures. These Non-GAAP measures are used by the Company to measure its performance and may differ from those used by other companies and these Non-GAAP measures should not be considered in isolation from, or as a substitute for, measures of financial performance prepared in accordance with U.S. GAAP. Management believes that these Non-GAAP measures are helpful as they provide a measure of the results of operations and are frequently used by investors and analysts to evaluate the Company's performance exclusive of certain items that impact the comparability of results from period to period, and which may not be indicative of past or future performance of the Company. Constant currency, adjusted operating income and margin, adjusted gross profit and margin, adjusted net income (loss), adjusted EBITDA and margin, adjusted earnings (loss) per diluted share, and Free Cash Flow are Non-GAAP measures on slide 15.

The Company does not provide forward-looking estimates on a GAAP basis as certain information, which may include, but is not limited to, restructuring charges, transformation-related costs, impairment charges, certain tax adjustments, and other significant items, is not available without unreasonable effort and cannot be reasonably estimated. The exact amounts of these charges or credits are not currently determinable but may be significant.

Percentages are based on actual values and may not reconcile due to rounding.

Key Developments

Building positive momentum in the U.S. through Return-to-Growth Action Plan

Record quarterly sales for Wellspect Healthcare; completed U.S. launch of Wellspect Surity™ portfolio

Accelerating execution of the redesigned North American Clinical Education program with 6x spend increase in H2 2026 YoY

Hosted DS World events with a 60% increase in workshops, lectures and hands-on CE courses versus prior year

U.S. Commercial recruitment and retention improved significantly

Updating FY2026 outlook to approximately $3.5 billion in net sales and adjusted EPS of $1.20 to $1.30



Note: The tariff refund benefits are not included in the updated 2026 outlook

Established North American Distributor Network



New Agreements Simplifying Operating Model

- Seven new distribution agreements signed YTD
- Simplified incentive structure and inventory model enabling operational efficiencies
- Driving growth through mutually beneficial relationships



Broadening Access to Capital Equipment

- Expanding commercial reach across North America and key regional markets
- Supporting practices to optimize workflows
- Enabling practices to deliver single-visit dentistry

Building U.S. Momentum to Support Return-to-Growth

U.S. Sales Force Investment: Signs of Progress

Stronger field coverage and capabilities are supporting early commercial gains

STABILIZING COVERAGE

Recruit & Retain

Improved significantly; attracting talent to further stabilize sales teams

Mid-single digits

Quota-carrying field vacancies, down from approximately 20%

BUILDING CAPABILITIES

100% certified

Premium implant sales force certification completed

MIS certification

MIS sales force to be certified by end of year

EARLY MIS RESULTS

Double-digit

U.S. MIS sales growth in Q3 versus prior year

More conversions

September MIS conversions increased sharply versus the historical monthly pace

Building on MIS momentum to deliver more consistent performance across the portfolio

We provide the education our customers need to adopt and use our solutions with confidence

Executing a step-change in clinical education investment in North America

Scaling hands-on training, digital access and clinician engagement across the dental community

6× **increase YoY**

Clinical education investment

>60% **Increase YoY**

Implants education engagements

>160 **Endo courses in H2**

Launch of high-impact, hands-on programs in North America

Education delivered across multiple channels

Education centers	Online learning platform	Forums & summits	Study clubs
Schools & universities	Events & congresses	Lunch & learns	Dental communities

Learning formats

Hands-on | Lectures | Virtual | Rep-led training | University events | Partner events | Symposia & summits

Early Signs of Progress Across Key Product Lines

Sales training and clinical education are supporting early gains in adoption and sales

	SALES MOMENTUM	ADOPTION & CUSTOMER ENGAGEMENT
ENDODONTICS 	**Reciproc Blue growth** Continued year-over-year growth, with total file sales also increasing.	**More repeat use** Reorder rates improved consistently throughout the year.
EDS 	**Focus brands recovering** Focus brands returned to growth; Cercon 4D added incremental sales.	**Stronger demand signals** Sell-out outpaced sell-in across Restorative and Preventive; new customer retention improved.
IMPLANTS 	**MIS growth** Americas sales grew year over year.	**More customer conversions** Conversions accelerated in September versus the historical monthly pace.


Focused commercial investment · Improving adoption · Building more consistent growth

Achieved Record Wellspect Sales Powered by Innovation

Completed Launch of Wellspect Surity™ Portfolio in the U.S.


Female External Catheter

- **Surity™** female external catheter launches with ease of use, discretion, and user comfort
- Launched January 2026



Male External Catheter

- **Surity™** male external catheter builds on expanding portfolio of incontinence management solutions
- Launched April 2026



Urinary Management System

- **Surity™ Urinary Management System,** a discreet at-home urine collection device
- Launched August 2026



Medicare Reimbursement

- **Surity™ portfolio,** may be covered by traditional Medicare for eligible beneficiaries when medically necessary
- Important step in expanding access and reducing barriers to at-home management
- Announced October 2026

Surity

Increased investment 15% YoY to further penetrate Urine Management market

Transformation Office Shifting from Stabilization to Value Creation



Stabilizing the Business

~$120M

savings initiative in 2026

Funding the reset and establishing stronger cost discipline

- **Operating Mechanism**
  Transformation Office, governance and accountability embedded
- **U.S. Growth Focus**
  Commercial actions prioritized around the largest growth engine
- **Simplification**
  Cost, process and organizational complexity addressed with urgency

Outcome: stabilized execution and developed repeatable engine for change

Scale the Model

01	**Quote-to-Cash** Simplify pricing, ordering, fulfillment, billing and collections	CUSTOMER EXPERIENCE
02	**Procure-to-Pay** Increase spend control, standardization and process automation	SG&A + CASH
03	**Standardize and Automize Workflows** Scale transactional work and capabilities	EFFICIENCY + SCALE

Target: lower SG&A, improved cash conversion and a more consistent customer experience

Third Quarter 2026 Financial Summary

Third Quarter 2026 Financial Summary

	Q3 2026	Q3 2025	YoY
Net Sales	**$836M**	$904M	(7.6%)
Constant Currency			(7.0%)
Adj. EBITDA	**$146M**	$167M	(13.3%)
Adj. EBITDA %	**17.3%**	18.4%	(110) bps
Adj. EPS	**$0.29**	$0.42	($0.13)
Operating Cash Flow	**$32M**	$79M	(59.5%)

Commentary

- **Net sales (7.6%) YoY**
  - Declines in EDS, CTS, and OIS, partially offset by Wellspect
  - Constant currency revenue down (7.0%)
- **Adj. EBITDA margin 17.3%, (110) bps YoY**
  - Lower volumes in dental segments
  - Continued OPEX investments
- **Operating Cash Flow of $32M**
  - Unfavorable working capital drove decline
  - $195M cash and cash equivalents

Commentary and trends are based on as reported vs. Q3 2025 unless otherwise noted
Constant currency, adjusted EBITDA, adjusted EBITDA %, and adjusted EPS are Non-GAAP measures as defined on slide 15

Third Quarter 2026 Segment Results

	Net Sales	As Reported	Constant Currency	Commentary
Connected Technology Solutions (CTS)	**$230M**	**(11.0%)**	**(10.1%)**	▪ CAD/CAM: Lower volumes in Americas driven by the planned shift in distributor inventory model ▪ Equipment & Instruments: Lower volumes of Imaging products globally, partially offset by Instruments growth in EMEA and Americas
Essential Dental Solutions (EDS)	**$343M**	**(4.0%)**	**(3.6%)**	▪ Decline driven by lower volumes of Endo products in EMEA and unfavorable pricing, partially offset by higher volumes of Endo files and Restorative blocks in the U.S.
Orthodontic and Implant Solutions (OIS)	**$171M**	**(16.6%)**	**(16.2%)**	▪ Orthodontics: Decline attributable to ($12M) Byte YoY impact and lower volumes in the U.S., partially offset by mid-single digit growth in EMEA ▪ Implants & Prosthetics: Lower premium implant volumes across all regions, partially offset by DD growth for value implants in the U.S.
Wellspect Healthcare	**$92M**	**10.1%**	**11.0%**	▪ Higher product volumes, partially driven by new product launches

Growth commentary and trends are based on as reported vs. Q3 2025
Constant currency sales are a Non-GAAP measure. The foreign currency impact is the only reconciling item between as reported and constant currency sales

Updated 2026 Outlook*

	Prior Outlook	Current Outlook
Net Sales	**$3.5B to $3.6B**	**$3.5B**
Adjusted EPS	**$1.40 to $1.50**	**$1.20 to $1.30**

*Actual results may differ materially due to a number of factors and risks, including those described in the Company's filings with the SEC
Note: The benefits of refunds for tariffs are not included in the outlook for 2026 adjusted EPS

Appendix

Dentsply Sirona

Non-GAAP Financial Measures Definitions

Constant Currency

Reported net sales adjusted for the impact of foreign currency changes, which is calculated by translating current period net sales using the comparable prior period's foreign currency exchange rates.

Adjusted Operating Income and Margin

Adjusted operating income is computed by excluding the following items from operating income (loss) as reported in accordance with US GAAP. Adjusted operating margin is calculated by dividing adjusted operating income by net sales.

- Business combination-related costs: costs related to consummating and integrating acquired businesses, as well as net gains and losses related to disposed businesses. Costs include the post-acquisition roll-off of fair value adjustments recorded related to business combinations, except for amortization expense of purchased intangible assets noted below.
- Restructuring-related charges and other costs: costs related to the implementation of restructuring initiatives, including but not limited to, severance costs, facility closure costs, and lease and contract termination costs, as well as related professional service costs associated with these restructuring initiatives and global transformation activity. Other costs include gains and losses on the sale of property, legal settlements, executive separation costs, write-offs of inventory as a result of product rationalization, and changes in accounting principles recorded within the period. This category also includes costs related to investigations and associated legal cases and remediation activities, which primarily include legal, accounting and other professional service fees, as well as turnover and other employee-related costs.
- Goodwill and intangible asset impairments: include charges related to goodwill and intangible asset impairments.
- Amortization of purchased intangible assets: includes the periodic amortization expense related to purchased intangible assets, which are recorded at fair value.
- Fair value and credit risk adjustments: include the non-cash mark-to-market changes in fair value associated with pension assets and obligations, the credit risk component of hedging instruments, contingent consideration from past acquisitions, and equity-method investments.

Adjusted Gross Profit and Margin

Gross profit excluding the impact of any of the above adjustments that affect either net sales or cost of sales. Adjusted gross margin is calculated by dividing adjusted gross profit by net sales.

Adjusted Net Income (Loss)

Net income (loss) as reported in accordance with US GAAP, adjusted to exclude the items identified above and the related income tax impacts of those items, as well as the tax effects of certain significant and discrete tax adjustments, including benefits and provisions related to changes in realization of deferred tax assets and tax credit carryforwards, as well as other events that affect comparability and are not core to our underlying operational performance.

Adjusted EBITDA and Margin

In addition to the adjustments described above in arriving at adjusted net income, adjusted EBITDA is computed by further excluding any remaining interest expense, net, income tax expense, depreciation and amortization. Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by net sales.

Adjusted Earnings (Loss) Per Diluted Share

Computed by dividing adjusted earnings (loss) attributable to Dentsply Sirona stockholders by the diluted weighted average number of common shares outstanding.

Free Cash Flow

Net cash provided by operating activities minus capital expenditures during the same period.

Net Sales as Reported and in Constant Currency
(unaudited)

Q3 2026 Results by Region and Segment (Reported and Non-GAAP)
(in millions, except percentages)

Net Sales by Segment			Percentage Change							
			Three Months Ended September 30, 2026 vs. 2025							
					Americas		EMEA		APAC	
	2026	2025	As Reported[1]	Constant Currency[1]	As Reported	Constant Currency	As Reported	Constant Currency	As Reported	Constant Currency
Connected Technology Solutions	$ 230	$ 259	(11.0)%	(10.1)%	(21.6)%	(21.9)%	(5.5)%	(4.2)%	(4.7)%	(2.5)%
Essential Dental Solutions	343	357	(4.0)%	(3.6)%	(0.6)%	(0.8)%	(7.7)%	(6.5)%	(4.4)%	(4.2)%
Orthodontic and Implant Solutions	171	205	(16.6)%	(16.2)%	(22.9)%	(23.1)%	(13.5)%	(12.3)%	(7.3)%	(7.2)%
Wellspect Healthcare	92	83	10.1%	11.0%	77.3%	78.6%	1.2%	2.0%	(1.0)%	4.1%
Total	$ 836	$ 904	(7.6)%	(7.0)%	(9.4)%	(9.6)%	(6.7)%	(5.6)%	(5.2)%	(4.3)%

(1) Constant currency sales are a Non-GAAP measure in which the reported net sales are adjusted for the impact of foreign currency changes, which is calculated by translating current period net sales using the comparable prior period's foreign currency exchange rates. The foreign currency impact is the only reconciling item between as reported and constant currency sales.

Reconciliation of Non-GAAP Financial Measures

Condensed Consolidated Statements of Operations

(in millions, except per-share amounts)

(unaudited)

Three Months Ended September 30, 2026	Gross Profit	Operating Income	Provision for Income Taxes	Net (Loss) Income Attributable to Dentsply Sirona	Diluted (Loss) Earnings per Share
Reported	$ 443	$ 37	$ 29	$ (2)	$ (0.01)
Reported percent net sales	52.9%	4.4%			
Non-GAAP Adjustments:					
Amortization of Purchased Intangible Assets	12	46	11	35	0.17
Restructuring-Related Charges and Other Costs (a)	1	10	2	8	0.04
Goodwill and Intangible Asset Impairments	—	3	1	2	0.01
Business Combination-Related Costs	—	—	—	—	—
Fair Value and Credit Risk Adjustments	—	(1)	—	(1)	—
Income Tax-Related Adjustments (b)	—	—	(17)	17	0.08
Adjusted	$ 456	$ 95	$ 26	$ 59	$ 0.29
Adjusted percent net sales	54.5%	11.5%			
Weighted average common shares outstanding used in calculating diluted GAAP net loss per common share					199.2
Weighted average common shares outstanding used in calculating diluted Non-GAAP net income per common share					200.2

(a) Restructuring-Related Charges and Other Costs includes costs from restructuring actions and the new global ERP system, partially offset by a $9 change in estimate for the 2026 restructuring plan. These amounts are on a pre-tax basis.

(b) Income Tax-Related Adjustments includes adjustments for increased valuation allowances for the U.S. of $12, Luxembourg of $3, and Switzerland of $2 and decreased valuation allowances for Germany of $5, along with other various tax adjustments.

Percentages are based on actual values and may not reconcile due to rounding.

Reconciliation of Non-GAAP Financial Measures

Condensed Consolidated Statements of Operations

(in millions, except per-share amounts)
(unaudited)

Three Months Ended September 30, 2025	Gross Profit	Operating (Loss) Income	Provision for Income Taxes	Net (Loss) Income Attributable to Dentsply Sirona	Diluted (Loss) Earnings per Share
Reported	$ 441	$ (218)	$ 198	$ (427)	$ (2.14)
Reported percent net sales	48.8%	(24.0%)			
Non-GAAP Adjustments:					
Amortization of Purchased Intangible Assets	33	56	15	41	0.21
Restructuring-Related Charges and Other Costs (a)	1	17	(3)	20	0.10
Goodwill and Intangible Asset Impairments	—	262	(1)	263	1.31
Business Combination-Related Costs	—	2	1	1	0.01
Income Tax-Related Adjustments (b)	—	—	(186)	186	0.93
Adjusted	$ 475	$ 119	$ 24	$ 84	$ 0.42
Adjusted percent net sales	52.6%	13.2%			
Weighted average common shares outstanding used in calculating diluted GAAP net loss per common share					199.5
Weighted average common shares outstanding used in calculating diluted Non-GAAP net income per common share					200.3

(a) Restructuring-Related Charges and Other Costs includes $5 in costs for the new global ERP system, $4 in costs from various restructuring actions related to employee severance, $4 in executive separation costs, and various other costs. Amounts are on a pre-tax basis.

(b) Income Tax-Related Adjustments includes adjustments for decreased valuation allowances for Luxembourg of $3, along with increased valuation allowances for Germany of $5 and Switzerland of $3, and other various tax adjustments.

Percentages are based on actual values and may not reconcile due to rounding.

Reconciliation of Non-GAAP Financial Measures

Adjusted EBITDA

(in millions)
(unaudited)

Reconciliations of reported net loss attributable to Dentsply Sirona to adjusted EBITDA and margin are as follows:

	Three Months Ended September 30,	
	2026	2025
Net loss attributable to Dentsply Sirona	$ (2)	$ (427)
Interest expense, net	25	23
Provision for income taxes	29	198
Depreciation[(1)]	36	36
Amortization of intangible assets	46	56
Restructuring-related charges and other costs	10	17
Goodwill and intangible asset impairments	3	262
Business combination-related costs and fair value adjustments	—	2
Fair value and credit risk adjustments	(1)	—
Adjusted EBITDA	$ 146	$ 167
Net sales	$ 836	$ 904
Adjusted EBITDA margin	17.3%	18.4%

(1) Excludes those depreciation-related amounts which were included as part of the business combination-related adjustments and Restructuring-related charges and other costs.
Percentages are based on actual values and may not reconcile due to rounding.

